News

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If you are wondering whether Halozyme Therapeutics at around US$68.41 is offering good value or asking too much, you are not alone. The share price performance has been mixed recently, with a 1.6% return over 7 days, 7.9% over 30 days, a 2.7% decline year to date, and a 17.5% return over the past year, alongside a 103.8% return over 3 years and 33.8% over 5 years. Recent coverage has focused on how Halozyme Therapeutics fits into broader biotech themes and how its partnerships and product...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology […]

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.